Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Henrik Ponten"'
Publikováno v:
Journal of Huntington's Disease
Despite advances in understanding the pathophysiology of Huntington’s disease (HD), there are currently no effective pharmacological agents available to treat core symptoms or to stop or prevent the progression of this hereditary neurodegenerative
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7221d80d9ae3fc0ecfd7c23e2523de62
https://doi.org/10.3233/jhd-170267
https://doi.org/10.3233/jhd-170267
Autor:
Henrik Ponten, Clas Sonesson, Theresa Andreasson, Ylva Sunesson, Johan Kullingsjö, Elisabeth Ljung, Peder Svensson, Nicholas Waters, Susanna Waters
Publikováno v:
ACS Chemical Neuroscience. 8:785-797
This paper describes the application of in vivo systems response profiling in CNS drug discovery by a process referred to as the Integrative Screening Process. The biological response profile, treated as an array, is used as major outcome for selecti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57de92644a871ce1918b7f86b7a9d120
https://doi.org/10.1021/acschemneuro.6b00371
https://doi.org/10.1021/acschemneuro.6b00371
The dopaminergic stabilizers pridopidine and ordopidine enhance cortico-striatal Arc gene expression
Publikováno v:
Journal of Neural Transmission. 121:1337-1347
The dopaminergic stabilizers pridopidine [4-(3-(methylsulfonyl)phenyl)-1-propylpiperidine] and ordopidine [1-ethyl-4-(2-fluoro-3-(methylsulfonyl)phenyl)piperidine] inhibit psychostimulant-induced hyperactivity, and stimulate behaviour in states of hy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::350c1f5c2d6a9f141416c34b2e9a2ebd
https://doi.org/10.1007/s00702-014-1231-1
https://doi.org/10.1007/s00702-014-1231-1
Autor:
Clas Sonesson, Fredrik Pettersson, Johan Kullingsjö, Sören Lagerkvist, Susanna Waters, Henrik Ponten, Nicholas Waters, Peter R. Martin
Publikováno v:
European Journal of Pharmacology. 644(1-3):88-95
Pridopidine (ACR16) belongs to a new pharmacological class of agents affecting the central nervous system called dopaminergic stabilizers. Dopaminergic stabilizers act primarily at dopamine type 2 (D(2)) receptors and display state-dependent behaviou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00bc9be72e933f4495b99a3afef8bf45
Publikováno v:
Journal of Medicinal Chemistry. 53:2510-2520
Modification of the partial dopamine type 2 receptor (D(2)) agonist 3-(1-benzylpiperidin-4-yl)phenol (9a) generated a series of novel functional D(2) antagonists with fast-off kinetic properties. A representative of this series, pridopidine (4-[3-(me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88639d1bc689c83c0d7744eb7b2dcb63
https://doi.org/10.1021/jm901689v
https://doi.org/10.1021/jm901689v
Publikováno v:
Journal of Huntington's disease. 3(3)
BACKGROUND The efficacy of the dopaminergic stabilizer, pridopidine, in reducing the voluntary and involuntary motor symptoms of Huntington's disease (HD) is under clinical evaluation. Tetrabenazine is currently the only approved treatment for chorea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7d0be273c6fe8f9664a77eca6b98e87
https://pubmed.ncbi.nlm.nih.gov/25300332
https://pubmed.ncbi.nlm.nih.gov/25300332
Autor:
Johan Kullingsjö, Stephan von Hörsten, Fabio Canneva, Yvonne K. Urbach, Huu Phuc Nguyen, Theresa Andreasson, Kerstin Raber, Olaf Riess, Henrik Ponten, Anne-C. Plank
Publikováno v:
Journal of neuroscience methods. 234
Background The need for improving throughput, validity, and reliability in the behavioral characterization of rodents may benefit from integrating automated intra-home-cage-screening systems allowing the simultaneous detection of multiple behavioral
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6514ce8bd03e5c0bbdfd64db5ec1a26
https://pubmed.ncbi.nlm.nih.gov/25020253
https://pubmed.ncbi.nlm.nih.gov/25020253
The dopaminergic stabilizer pridopidine demonstrates state-dependent effects on locomotor activity, counteracting both hypo- and hyperactivity in rats. Pridopidine has been shown to display both functional dopamine D2 receptor antagonist properties a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4355b958467594a4e79743499e79f39d
Autor:
Henrik Ponten, Johan Kullingsjö, Nicholas Waters, Joakim Tedroff, Clas Sonesson, Susanna Waters
Publikováno v:
European journal of pharmacology. 698(1-3)
Treatment-limiting motor complications occur in patients with Parkinson's disease after chronic levodopa (L-DOPA) treatment, and represent an unmet medical need. We examined the motor and neurochemical effects of the dopaminergic stabilizer pridopidi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b73d63da9a2dc70ab8727feaa704c37
https://pubmed.ncbi.nlm.nih.gov/23127496
https://pubmed.ncbi.nlm.nih.gov/23127496
Autor:
Laurent Groc, Kirsten Sönniksen, Nicholas Waters, Therése Abrahamsson, Bengt Gustafsson, Eric Hanse, Henrik Ponten
Publikováno v:
Brain research. Developmental brain research. 155(1)
Early destruction of the ventral hippocampus from postnatal day 7 (P7) has been shown to induce behavioral alterations in post-pubertal rats, similar to those observed in models for schizophrenia. Using a single injection of tetanus toxin into the ve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4187d2657a95a96ad9e25313325b6eea
https://pubmed.ncbi.nlm.nih.gov/15763278
https://pubmed.ncbi.nlm.nih.gov/15763278